Pleiotropic effects of statins;Efectos pleiotrópicos de las estatinas

Revista Medica de Chile

Volumn 136, Issue 6, 2008, Pages 775-782

  Mennickent C, Sigrid ^a   Bravo D, Marisol ^a   Calvo M, Carlos ^a   Avello L, Marcia ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Coronary disease; Hydroxymethylglutaryl CoA reductase inhibitors; Intracellular signaling peptides and proteins

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; FLUINDOSTATIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MEVINOLIN; MONOUNSATURATED FATTY ACID; PRAVASTATIN; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; OXIDATIVE STRESS; REVIEW; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LOVASTATIN; OXIDATIVE STRESS; PRAVASTATIN; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 51349121453     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. OSCAR R, GARAY M, OLIVILLO N. Estatinas: Prevención Primaria y Secundaria de la Hipercolesterolemia. Revista de Postgrado de la VI cátedra de medicina, Universidad Nacional del Nordeste, Corrientes, Argentina 2003; 125: 15.
2. LAUFS U, WASSMANN S, SCHACKMANN S, HAESCHEN C, BOPHM M, NICKENING G. Beneficial effects of statins in patients with non-isdchemic heart failure. Z Kardiol 2004; 93: 103-8.
3. ACEVEDO S, AGUILLÓN R. Manejo de dislipidemias en pacientes diabéticos tipo 2. Revista MedUNAB 2004; 6: 3.
4. a Ed., Mc Graw-Hill, México 2003.
5. a Ed., Pharma Editores S.L, Barcelona 2003.
6. a Ed., American Society of Health System Pharmacists, Bethesda 2006.
7. a Ed., Mosby Year Book, St. Louis 1994.
8. a Ed., Lippincott-Raeven, Philadelphia 1998.
9. KATZUNG B. Farmacología Básica y Clínica. Editorial El Manual Moderno, México 1999.
10. a Ed., Elsevier Academic Press, Amsterdam 2004.
11. PAGE C, CURTIS N, SUTTER M, WALKER M, HOFFMAN B. Farmacología Integrada, Harcout, Madrid 1998.
12. YATES T, MENNICKENT S, VILLEGAS G. Texto de Farmacoquímica. Aspectos Esructurales y Propiedades de los Medicamentos, Editorial Universidad de Concepción, Concepción 2004.
13. a Ed., John Wiley & Sons, Inc., New York 1995.
14. BELTOWSKI J. Statins and Modulation of Oxidative Stress. Toxicology Mechanism and Methods 2005; 15: 61.
15. a Ed., Merck & Co, NJ 2001.
16. LIAO J, LAUFS U. Pleoitropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
17. ARTEAGA E, POLLAK F. Dislipidemias en la práctica clínica, International Lipid Information Bureau, Santiago de Chile 2002.
18. a Ed., Editorial Reverté S.A., Barcelona 1995.
19. VAUGHAN CJ, GOTTO AM JR, BASSON CT. The envolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 31: 1-10.
20. ISTVAN ES, DEISENHOFER J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-4.
21. FONCEA R, CARVAJAL C, LEIGHTON F. Endothelial cell oxidative stress and signal transduction. Biological Research 2000; 33: 86-96.
22. PARK HJ, KONG D, IRUELA-ARISPE L, BEGLEY U, TANG D, GALPER JB. 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-50.
23. MACCARTHY PA, GRIEVE DJ, LI MJ, DUNSTER C, KELLY FJ, SHAH AM. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 2001; 104: 2967-74.
24. 91 (phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002; 105: 293-6.
25. LI JM, GALL NP, GRIEVE DJ, CHEN M, SHAH AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002; 40: 477-84.
26. NAKAGAMI H, TAKEMOTO M, LIAO JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003; 35: 851-9.
27. XIAO L, PIMENTEL DR, WANG J, SINGH K, COLUCCI WS, SAWYER DB. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 2002; 282: C926-934.
28. LEFER AM, SCALIA R, LEFER DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281-7.
29. YANG Z, KOZAI T, VAN DER LOO B, VISWAMBHARAN H, LACHAT M. HMG-CoA reductase inhibitors improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000; 36: 1691-7.
30. . LAUFS U, GERTZ H, HUANG P, NICKENIG G, BOHM M. Atorvastatin up-regulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2442-9.
31. FUKUMOTO Y, LIBBY P, RABKIN E, HILL CC, ENOMOTO M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe hyperlipidemic rabbits. Circulation 2001; 103: 993-9.
32. STALKER TJ, LEFER AM, SCALIA R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mvalonic acid. Br J Pharmacol 2001; 133: 406-12.
33. CARR AC, MC CALL MR, FREI B. Oxidation of LDL by mieloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscl Throm Vasc Biol 2000; 20: 1716-23.
34. KUREISHI Y, LUO Z, SHIOJIMA I, BIALIK A, FULTON D. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
35. VIDAL F, COLOME C, MARTÍNEZ- GONZÁLEZ J, BADIMON L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endotelial cells. Eur Biochem 1998; 252: 378-84.
36. SCHUSTER H. Effects of swittching to rosuvastatin from atorvastatin or other statins on acievement of international low-density lipoprotein cholesterol goals: MERCURY I trial. J Am Cardiol 2003; (Suppl): 227A-228A.
37. JONES PH. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high-density lipoprotein cholesterol results. J Am Cardiol 2003; (Suppl): 315A-316A.
38. BLASETTO JW, STEIN EA, BROWN W. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91: 3C-10C.